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Urinary proteomics in nephropathies some proteins were verified by Western blot and ELISA test.
Results
In diabetes-related study, 11 differentially expressed proteins were detected (8 up-regulated and 3 down-regulated) in type 2 diabetic (T2D) and T2DN patients compared to the healthy control subjects. In the MOH study, a total of 21 over-excreted proteins were revealed in urine of non-steroidal anti-inflammatory drugs (NSAIDs) and mixtures abusers vs controls. Particularly, 4 proteins were positively validated by immunoblotting and ELISA.
Conclusion
Urinary proteomics allows non-invasive assessment of renal diseases at an early stage by the identification of characteristic protein pattern.
INTRODUCTION
Proteomics is the study of protein expression in a definite tissue, cell type or biological body fluid. The comparison of protein patterns between healthy subjects and patients with a given pathological condition can be useful to identify specific diagnostics or prognostics biomarkers of diseases. Particularly, urinary proteomics has rapidly developed and has been extensively applied in the field of early diagnostics and differentiation of renal damage (1).
Urine is a valuable source of proteins and peptides; it has the advantage of being obtained non-invasively, easily and frequently, and in a large quantity. It has been defined as a fluid biopsy of the kidney and urogenital tract, thus providing considerable information about these organs. Consequently, many changes in kidney and urogenital tract function may be detected in the urinary proteome (2) .
Urine proteomics studies were conducted in the search for early biomarkers of renal changes in:
1. type 2 diabetic nephropathy (T2DN), a complication linked to diabetes, which leads to end-stage renal disease (3);
2. drug-induced nephrotoxicity in medicationoveruse headache (MOH), a chronic disorder associated with overuse of analgesic drugs or compounds for acute headache (4-6).
MATERIALS AND METHODS

Subjects
1) Diabetic nephropathy
Diabetic patients were enrolled from the "Division of Nephrology, Dialysis and Renal Transplantation" of the University-Hospital of Modena and Reggio Emilia, Italy: 10 normoalbuminuric patients with type 2 diabetes (T2D), 12 T2DN patients with microalbuminuria (range 130-280 mg/mL) and/or proteinuria (>10 mg/ dL), and a control group of 12 healthy volunteer subjects with a history of regular renal function.
The duration of diabetes was similar in the two patients groups. Moreover, all groups were matched for age and gender (3). together with other important illness, were considered as exclusion criteria (5) .
2) Drug-induced nephrotoxicity
Both studies were in compliance with the ethical principles for medical research involving human subjects, in accordance with the Declaration of Helsinki. Written informed consent were received from both, patients and healthy subjects.
Urine proteomics analysis
Morning midstream urine samples were collected and immediately centrifuged at 800 g for 10 min at +4C°, to remove cell debris and contami- spectrophotometric Bradford method, and 100 mg of protein was premixed with a specific lysis buffer. The first-dimension separation (isoelectrofocalization) was performed using IPG strips 17 cm long, wide pH range 3-10 (Bio-Rad), while in the second-dimension separation, 8-16% polyacrylamide gradient gels were used, that finally were staining with a silver-nitrate staining protocol. Afterwards, gels images were acquired with a calibrated densitometer (GS800 model, Bio-Rad) and analyzed by a specific image analysis software (PDQuest, Bio-Rad), to reveal differentially expressed protein spots among the patients and control groups (3, 5) . The spots of interest were cut from the gels and subjected to trypsin digestion. Peptides were finally extracted and analyzed by the mass spectrometry using a quadrupole-time of flight-liquid chromatography mass spectrometer (Q-ToF-LC/MS,
Agilent-Technologies).
In the second study (drug-induced nephrotoxicity), the results obtained by proteomic analysis
were further confirmed and validated by Western blot and ELISA test (6) .
RESULTS AND DISCUSSION
1) Diabetic nephropathy
Comparing the urinary proteomic profiles obtained by 2-DE analysis, 11 differential proteins were identified that progressively changed between controls and T2D and T2DN patients. Precisely, 8 proteins were significantly up-regulated: transthyretin precursor, Ig k chain C region, Ig k chain V-II region Cum, Ig k-chain V-III region SIE, carbonic anhydrase 1, retinol binding protein, beta-2-microglobulin precursor and beta-2-glycoprotein 1.
Except for the last one, all the other proteins were in the low MW range (<30 kDa). Three proteins were found down-regulated: prostatic acid phosphatase precursor, ribonuclease 2 and kallikrein-3 (Table 1) .
Proteomic analysis allowed to detect alterations of urinary proteins in both T2DN and T2D
Protein name
Acc. number normo albuminuric patients. Thus, this protein pattern might be of potential interest to identify diabetic patients prone to develop nephropathy, contributing to a better understanding of diabetic-related renal damage. The strength of proteomics in this research area has been confirmed also by recently published review articles (7, 8) .
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2) Drug-induced nephrotoxicity
In this study, both qualitative and quantitative differences in urine of MOH patients were studied and revealed. Interestingly, by 2-DE combined with MS analysis, 21 over-excreted proteins and a significantly higher number of total protein spots were identified in the urine of NSAIDs, mixtures and triptans abusers compared to the controls (Table 2) . Some differentially expressed proteins detected by proteomic analysis were found to be strongly related to renal injury (9) , as assessed by an extensive literature review. Particularly, 4 proteins were validated by Western blot: prostaglandin-H2 D-synthase (PTGDS), uromodulin (UROM), alpha-1-microglobulin (AMBP) and cystatin-C (CYSC), as shown in Figure 1 .
Immunoblotting allowed to confirm previous data of over-expression of these proteins in urine of MOH patients (especially NSAIDs and mixtures abusers) vs normal controls (6).
Finally, PTGDS was further quantified by the ELISA test (Figure 2 ), which proved its significant increase in all MOH groups: mixtures (681 ± 218 ng/mL), NSAIDs (572 ± 135 ng/mL,) and triptans (450 ± 116 ng/mL), compared to the controls (303 ± 130 ng/mL). These data points, The results of this study allowed to define the urinary protein profile of MOH, in relation to the type of drug abused. The use of powerful proteomic methodologies could permit to identify promising candidate biomarkers of kidney dysfunctions, and consequently those chronic headache patients at risk to develop drug-induced nephrotoxicity.
CONCLUSIONS
In conclusion, urinary proteomics proved to be a suitable tool in nephro-toxicological research. Actually, its application may be useful in the search of early biomarkers, providing important diagnostics and prognostics indications.
Additionally, the study of the urinary proteome can offer significant data for a better understanding of renal pathophysiology. vs controls).
